AlvotechALVO
About: Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
Employees: 1,032
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
33% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]
2% more funds holding
Funds holding: 50 [Q1] → 51 (+1) [Q2]
0.17% more ownership
Funds ownership: 5.52% [Q1] → 5.69% (+0.17%) [Q2]
2% less capital invested
Capital invested by funds: $159M [Q1] → $155M (-$3.72M) [Q2]
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
UBS | 70%upside $14 | Buy Maintained | 18 Jul 2025 |
Financial journalist opinion
Based on 11 articles about ALVO published over the past 30 days









